Table 2.
Patient characteristics
| Overall | sPP | mPP | Cisplatin‐based | Carboplatin‐based | |
|---|---|---|---|---|---|
| N° (%) | N° (%) | N° (%) | N° (%) | N° (%) | |
| Patients (N°) | 111 | 87 | 24 | 76 | 35 |
| Age, years | |||||
| Range | 24–82 | 24–76 | 55–82 | 33–79 | 24–82 |
| Mean | 63.0 | 60.7 | 71.6 | 61.4 | 66.6 |
| Median | 66.0 | 64.0 | 73.0 | 64.5 | 67.0 |
| Gender | |||||
| Male | 75 (67.6) | 58 (66.7) | 17 (70.8) | 52 (68.4) | 23 (65.7) |
| Female | 36 (32.4) | 29 (33.3) | 7 (29.2) | 24 (31.6) | 12 (34.3) |
| Age | |||||
| Non‐elderly | 50 (45.0) | 47 (54.0) | 3 (12.5) | 38 (50) | 12 (34.3) |
| Young‐elderly | 46 (41.5) | 34 (39.1) | 12 (50) | 35 (46.1) | 11 (31.4) |
| Old‐elderly | 15 (13.5) | 6 (6.9) | 9 (37.5) | 3 (3.9) | 12 (34.3) |
| ECOG PS | |||||
| 0 | 61(55.0) | 53 (60.9) | 8 (33.3) | 55 (72.3) | 6 (17.2) |
| 1 | 44 (39.6) | 33 (37.9) | 11 (45.8) | 19 (25.0) | 25 (71.4) |
| 2 | 6 (5.4) | 1 (1.2) | 5 (20.9) | 2 (2.7) | 4 (11.4) |
| CIRS | |||||
| Primary | 41 (36.9) | 40 (46.0) | 1 (4.2) | 37 (48.7) | 4 (11.4) |
| Intermediate | 45 (40.6) | 35 (40.2) | 10 (41.7) | 30 (39.5) | 15 (42.9) |
| Secondary | 25 (22.5) | 12 (13.8) | 13 (54.1) | 9 (11.8) | 16 (45.7) |
| EGFR mutation status | |||||
| Wild‐type | 102 (91.9) | 80 (92.0) | 22 (91.7) | 71 (93.4) | 28 (88.6) |
| Mutant | 2 (1.8) | 2 (2.3) | — | 2 (2.7) | — |
| Not tested | 7 (6.3) | 5 (5.7) | 2 (8.3) | 3 (3.9) | 4 (11.4) |
| ALK rearrangement | |||||
| Positive | 7 (6.3) | 6 (6.9) | 1 (4.2) | 5 (6.6) | 2 (5.7) |
| Negative | 40 (36.0) | 33 (37.9) | 7 (29.2) | 26 (34.2) | 4 (11.4) |
| Not tested | 64 (57.7) | 48 (55.2) | 16 (66.6) | 45 (59.2) | 19 (82.9) |
| Previous adjuvant therapy | 5 (4.5) | 4 (4.6) | 1 (4.2) | 4 (5.3) | 1 (2.9) |
| Sites of metastasis | |||||
| Lung | 84 (75.7) | 65 (74.7) | 19 (79.1) | 56 (73.7) | 25 (71.4) |
| Liver | 14 (12.6) | 10 (11.5) | 4 (16.7) | 8 (10.5) | 6 (17.2) |
| Lymph nodes | 88 (79.3) | 72 (82.8) | 16 (66.6) | 55 (72.3) | 33 (94.3) |
| Bone | 37 (33.3) | 29 (33.3) | 8 (33.3) | 20 (26.3) | 17 (48.6) |
| Other | 29 (26.1) | 22 (25.3) | 7 (29.2) | 20 (26.3) | 9 (25.7) |
| Central nervous system metastasis | 22 (19.8) | 18 (20.7) | 4 (16.7) | 13 (17.1) | 9 (25.7) |
| Single | 5 (4.5) | 5 (5.7) | — | 3 (3.9) | 2 (5.7) |
| Multiple | 17 (15.3) | 13 (14.9) | 4 (16.7) | 10 (13.2) | 7 (20) |
CRIS, Cumulative Index Rating Scale; ECOG, Eastern Cooperative Oncology Group; mPP, modified platinum‐pemetrexed; sPP, standard PP.